Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
12 hedge funds and large institutions have $8.59M invested in Avenue Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
56% more capital invested
Capital invested by funds: $5.51M → $8.59M (+$3.08M)
9% more funds holding
Funds holding: 11 → 12 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$672K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$347K |
| 3 |
BlackRock
New York
|
+$116K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$28.9K |
| 5 |
Renaissance Technologies
New York
|
+$23.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$86.8K |
| 2 |
SIM
Spark Investment Management
New York
|
-$34.7K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$23.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $5.86M | +$672K | +116 | +16% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $625K | – | – | – |
|
|
EI
3
EAM Investors
Solana Beach,
California
| $474K | -$86.8K | -15 | -18% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $427K | +$347K | +60 | New |
|
|
BRWA
5
B. Riley Wealth Advisors
Boca Raton,
Florida
| $408K | +$28.9K | +5 | +9% |
|
|
6
BlackRock
New York
| $251K | +$116K | +20 | +133% |
|
|
SIM
7
Spark Investment Management
New York
| $148K | -$34.7K | -6 | -22% |
|
|
FWM
8
Frontier Wealth Management
Kansas City,
Missouri
| $126K | – | – | – |
|
|
9
Renaissance Technologies
New York
| $101K | +$23.2K | +4 | +40% |
|
10
Northern Trust
Chicago,
Illinois
| $92K | – | – | – |
|
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $42K | -$23.2K | -4 | -40% |
|
12
UBS Group
Zurich,
Switzerland
| $36K | +$5.79K | +1 | +25% |
|
|
13
Bank of America
Charlotte,
North Carolina
| – | -$1K | – | – |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$2K | – | – |
|
ATXI Hedge Fund Activity: Q2 2019 in Review
12 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2019, worth a combined $8.59M — up 56% from $5.51M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ATXI positions and 0 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Opaleye Management, adding an estimated $672K. The largest seller was EAM Investors, cutting an estimated $86.8K.
- 12 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2019, up from 11 in Q1 2019.
- Funds reported $8.59M of Avenue Therapeutics, Inc. Common Stock stock for Q2 2019, up 56% quarter-over-quarter.
- 1 fund opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +1 holder.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2019 was Opaleye Management, an estimated $672K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2019 was EAM Investors, an estimated $86.8K sold.
Based on aggregated 13F filings for Q2 2019.